Biologic switching in psoriatic arthritis: Insights from real-world data and key risk factors
Semin Arthritis Rheum. 2025;73:152737 doi: 10.1016/j.semarthrit.2025.152737
Haddad et al. used real-world data from Israel’s largest health maintenance organisation to investigate predictors and patterns of biologic therapy switching in PsA, reporting that nearly half of biologic users switched therapy at least once. Cross-class switching, particularly from anti-TNF to IL-17 therapies, was frequent and consistent across two decades of treatment data.